Skip to content
Menu

Barclays Maintains Overweight on Viatris, Raises Price Target to $25

Benzinga Newsdesk 17 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $22 to $25.

Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $22 to $25.

Read at benzinga.com